View Author
patient myeloma treatment study bortezomib therapy response dexamethasone thalidomide blood group trial survival lenalidomide cancer result analysis phase disease month leukemia table cycle factor expression combination university level signi regimen cytogenetic grade transplantation hospital number chemotherapy outcome effect myeloma patients agent induction neuropathy myeloid leukemia cell transplantation protein high-dose marrow plasma center vault randomized signi ficantly department melphalan progression prognostic event value relapse novel agents abnormality serum novel erasmus mc hematology sample ef ficacy response rate oncol prednisone maintenance erasmu autologou myeloid diagnosis cytarabine j clin oncol doxorubicin difference chromosome
10 Most Recent Publications
|
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma
(Article)
Voorhees, P.M. Manges, R.F. Orlowski, R.Z. Kranenburg, B. Hall, D.B. Casneuf, T. Qin, X. Velde, H. van de Xie, H. Thomas, S.K. Sonneveld, P. Jagannath, S. Somlo, G. Krishnan, A. Lentzsch, S. Frank, R.C. Zweegman, S. Wijermans, P.W. |
2013-05-01
|
|
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group
(Article)
Thielen, N. Holt, B. van der Schipperus, M.R. Schattenberg, A.V.M.B. Marwijk Kooy, R. van Smit, W.M. Chu, I.W.T. Valk, P.J.M. Ossenkoppele, G.J. Cornelissen, J.J. Verhoef, G.E.G. Ammerlaan, R.A.H.M. Sonneveld, P. Janssen, J.J.W.M. Deenik, W. Falkenburg, J.H.F. Kersten, M.J. Sinnige, H. |
2013-04-10
|
|
Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
(Article)
Fernández De Larrea, C. Kyle, R. Kumar, S. Mahindra, A. Comenzo, R.L. Palumbo, A. Mazumber, A. Anderson, K.C. Richardson, P.G. Badros, A.Z. Caers, J. Cavo, M. Durie, B.G.M. Leleu, X. Dimopoulos, M.A. Chim, C.S. Schots, R. Noeul, A. Fantl, D. Mellqvist, U.H. Landgren, O. Chanan-Khan, A. Moreau, P. Ludwig, H. Fonseca, R. Merlini, G. Lahuerta, J.J. Bladé, J. Orlowski, R.Z. Shah, J.J. Usmani, S.M. Vesole, D. Hajek, R. San Miguel, J-F. Sezer, O. Sonneveld, P. |
2013-04-01
|
|
Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents
(Article)
Gaultney, J.G. Franken, M. Tan, S.S. Orlewska, E. Huijgens, P.C. Sonneveld, P. Uyl-de Groot, C.A. |
2013-02-01
|
|
Disease control in patients with relapsed and/or refractory multiple myeloma: What is the optimal duration of therapy?
(Article)
Ludwig, H. Sonneveld, P. |
2012-11-01
|
|
Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: Results from a population-based study using the PROFILES registry
(Article)
Mols, F. Oerlemans, S. Vos, A.H. Koster, A. Verelst, S.G.R. Sonneveld, P. Poll-Franse, L.V. van de |
2012-10-01
|
|
Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: Results from a population-based study using the PROFILES registry
(Article)
Mols, F. Oerlemans, S. Vos, A.H. Koster, A. Verelst, S.G.R. Sonneveld, P. Poll-Franse, L.V. van de |
2012-10-01
|
|
Novel anticancer agents for multiple myeloma: A review of the evidence for their therapeutic and economic value
(Article)
Gaultney, J.G. Orlewska, E. Sonneveld, P. Uyl-de Groot, C.A. |
2012-06-01
|
|
How to manage neutropenia in multiple myeloma
(Article)
Palumbo, A. Bladé, J. Spencer, A. Sonneveld, P. San Miguel, J-F. Boccadoro, M. Palladino, C. Davies, F. Dimopoulos, M.A. Dmoszynska, A. Einsele, H. Moreau, P. Sezer, O. |
2012-02-01
|
|
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
(Article)
Neben, K. Lokhorst, H.M. Scheid, C. Dührsen, U. Lindemann, W. Schmidt-Wolf, I.G.H. Peter, N. Teschendorf, C. Martin, H. Haenel, M. Derigs, H.G. Raab, M.S. Jauch, A. Ho, A.D. Velde, C.J.H. van de Hose, D. Sonneveld, P. Goldschmidt, H. Bertsch, U. Hielscher, T. Holt, B.D. van Salwender, H. Blau, I.W. Weisel, K. Pfreundschuh, M. |
2012-01-26
|
